The stock of Uniqure NV (NASDAQ:QURE) reached all time low today, Nov, 30 and still has $6.08 target or 3.00% below today’s $6.27 share price. This indicates more downside for the $152.44 million company. This technical setup was reported by Barchart.com. If the $6.08 PT is reached, the company will be worth $4.57M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 44,838 shares traded hands. Uniqure NV (NASDAQ:QURE) has declined 52.80% since April 27, 2016 and is downtrending. It has underperformed by 58.03% the S&P500.
Analysts await Uniqure NV (NASDAQ:QURE) to report earnings on December, 5. They expect $-0.86 earnings per share, down 14.67% or $0.11 from last year’s $-0.75 per share. After $-0.98 actual earnings per share reported by Uniqure NV for the previous quarter, Wall Street now forecasts -12.24% EPS growth.
Uniqure NV (NASDAQ:QURE) Ratings Coverage
Out of 11 analysts covering uniQure N.V. (NASDAQ:QURE), 8 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 73% are positive. uniQure N.V. has been the topic of 21 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Roth Capital reinitiated Uniqure NV (NASDAQ:QURE) rating on Monday, November 30. Roth Capital has “Buy” rating and $37 price target. The firm has “Buy” rating given on Thursday, October 1 by Chardan Capital Markets. Jefferies downgraded Uniqure NV (NASDAQ:QURE) on Tuesday, November 22 to “Hold” rating. The firm has “Buy” rating by Piper Jaffray given on Monday, September 21. The rating was initiated by WallachBeth Capital with “Buy” on Friday, August 7. The stock has “Buy” rating given by Janney Capital on Tuesday, December 1. The firm has “Buy” rating given on Tuesday, December 1 by WallachBeth Capital. On Friday, August 28 the stock rating was maintained by WallachBeth Capital with “Buy”. The firm earned “Outperform” rating on Monday, September 21 by Oppenheimer. The firm has “Buy” rating given on Thursday, August 27 by Chardan Capital Markets.
According to Zacks Investment Research, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.”
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.